GP120-depleted HIV-1 vaccine (Salk Institute/Immune Response BioPharma)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameGP120-depleted HIV-1 vaccine (Salk Institute/Immune Response BioPharma)
Drug Alias NameHIV vaccine (Salk Institute/Immune Response BioPharma)GP120贫乏的HIV-1疫苗RemuneIR-8101RG-83894 +[6] 
ClassificationVaccines > Biological material > Viral vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsWeight LossLung NeoplasmsGastrointestinal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSalk Institute
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Rochester
Inactive CompaniesCanadian Institutes Of Health Research (Cihr)Agouron Pharmaceuticals LlcThe Immune Response Co +[6] 
Active IndicationsWeight LossLung NeoplasmsGastrointestinal Neoplasms +[4] 
Inactive IndicationsAcquired Immunodeficiency SyndromeHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A